Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
PR Newswire
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 15, 2026
MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chronic TEDMHB018A was generally well tolerated among 98 treated patients, demonstrating an excellent safety profile, with all hearing-related adverse events reported as Grade 1 and no severe or permanent hearing damageMHB018A is being evaluated in ongoing Phase III trials in China, with topline results anticipated in Q3 2026; global Phase III trials have been initiated, with first patient enrollment targeted for Q4 2026SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 15, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today presented complete Phase I/II clinical data of MHB018A, a novel subcutaneous anti-IGF-1R antibody, in patients with active and chronic thyroid eye disease ("TED"). The data were featured in an oral presentation at ENDO 2026, the Endocrine Society's Annual Meeting (Chicago, USA).
